Share-based Payment Arrangement, Expense of Cocrystal Pharma, Inc. from 31 Mar 2016 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Cocrystal Pharma, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Mar 2016 to 30 Sep 2025.
  • Cocrystal Pharma, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $48,000, a 81% decline year-over-year.
  • Cocrystal Pharma, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $282,000, a 19% decline year-over-year.
  • Cocrystal Pharma, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $643,000, a 20% decline from 2023.
  • Cocrystal Pharma, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $801,000, a 6.3% decline from 2022.
  • Cocrystal Pharma, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $855,000, a 18% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Cocrystal Pharma, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $282,000 $48,000 -$204,000 -81% 01 Jul 2025 30 Sep 2025 10-Q 14 Nov 2025 2025 Q3
Q2 2025 $486,000 $84,000 -$82,000 -49% 01 Apr 2025 30 Jun 2025 10-Q 14 Aug 2025 2025 Q2
Q1 2025 $568,000 $82,000 -$75,000 -48% 01 Jan 2025 31 Mar 2025 10-Q 15 May 2025 2025 Q1
Q4 2024 $643,000 $68,000 +$294,000 01 Oct 2024 31 Dec 2024 10-K 31 Mar 2025 2024 FY
Q3 2024 $349,000 $252,000 -$305,000 -55% 01 Jul 2024 30 Sep 2024 10-Q 14 Nov 2025 2025 Q3
Q2 2024 $654,000 $166,000 -$13,000 -7.3% 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2025 2025 Q2
Q1 2024 $667,000 $157,000 -$134,000 -46% 01 Jan 2024 31 Mar 2024 10-Q 15 May 2025 2025 Q1
Q4 2023 $801,000 $226,000 +$271,000 +55% 01 Oct 2023 31 Dec 2023 10-K 31 Mar 2025 2024 FY
Q3 2023 $530,000 $557,000 -$86,000 -13% 01 Jul 2023 30 Sep 2023 10-Q 13 Nov 2024 2024 Q3
Q2 2023 $616,000 $179,000 -$291,000 -62% 01 Apr 2023 30 Jun 2023 10-Q 14 Aug 2024 2024 Q2
Q1 2023 $907,000 $291,000 +$52,000 +22% 01 Jan 2023 31 Mar 2023 10-Q 13 May 2024 2024 Q1
Q4 2022 $855,000 $497,000 -$719,000 -324% 01 Oct 2022 31 Dec 2022 10-K 28 Mar 2024 2023 FY
Q3 2022 $1,574,000 $643,000 +$438,000 +214% 01 Jul 2022 30 Sep 2022 10-Q 13 Nov 2023 2023 Q3
Q2 2022 $1,136,000 $470,000 +$392,000 +503% 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023 2023 Q2
Q1 2022 $744,000 $239,000 +$20,000 +9.1% 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023 2023 Q1
Q4 2021 $724,000 $222,000 +$288,000 01 Oct 2021 31 Dec 2021 10-K 29 Mar 2023 2022 FY
Q3 2021 $436,000 $205,000 -$297,000 -59% 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022 2022 Q3
Q2 2021 $733,000 $78,000 -$41,000 -34% 01 Apr 2021 30 Jun 2021 10-Q 15 Aug 2022 2022 Q2
Q1 2021 $774,000 $219,000 +$112,000 +105% 01 Jan 2021 31 Mar 2021 10-Q 11 May 2022 2022 Q1
Q4 2020 $662,000 $66,000 -$163,000 -168% 01 Oct 2020 31 Dec 2020 10-K 23 Mar 2022 2021 FY
Q3 2020 $825,000 $502,000 +$394,000 +365% 01 Jul 2020 30 Sep 2020 10-Q 15 Nov 2021 2021 Q3
Q2 2020 $431,000 $119,000 +$6,000 +5.3% 01 Apr 2020 30 Jun 2020 10-Q 16 Aug 2021 2021 Q2
Q1 2020 $425,000 $107,000 +$74,000 +224% 01 Jan 2020 31 Mar 2020 10-Q 17 May 2021 2021 Q1
Q4 2019 $351,000 $97,000 01 Oct 2019 31 Dec 2019 10-K 17 Mar 2021 2020 FY
Q3 2019 $108,000 -$12,000 -10% 01 Jul 2019 30 Sep 2019 10-Q 13 Nov 2020 2020 Q3
Q2 2019 $113,000 +$6,000 +5.6% 01 Apr 2019 30 Jun 2019 10-Q 06 Aug 2020 2020 Q2
Q1 2019 $33,000 -$72,000 -69% 01 Jan 2019 31 Mar 2019 10-Q 13 May 2020 2020 Q1
Q3 2018 $120,000 -$22,000 -15% 01 Jul 2018 30 Sep 2018 10-Q 09 Nov 2018 2018 Q3
Q2 2018 $107,000 +$53,000 +98% 01 Apr 2018 30 Jun 2018 10-Q 09 Aug 2018 2018 Q2
Q1 2018 $105,000 -$107,000 -50% 01 Jan 2018 31 Mar 2018 10-Q 10 May 2018 2018 Q1
Q3 2017 $142,000 01 Jul 2017 30 Sep 2017 10-Q 09 Nov 2018 2018 Q3
Q2 2017 $54,000 -$665,000 -92% 01 Apr 2017 30 Jun 2017 10-Q 09 Aug 2018 2018 Q2
Q1 2017 $212,000 -$507,000 -71% 01 Jan 2017 31 Mar 2017 10-Q 10 May 2018 2018 Q1
Q2 2016 $719,000 01 Apr 2016 30 Jun 2016 10-Q 08 Aug 2017 2017 Q2
Q1 2016 $719,000 01 Jan 2016 31 Mar 2016 10-Q 10 May 2017 2017 Q1

Cocrystal Pharma, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $643,000 -$158,000 -20% 01 Jan 2024 31 Dec 2024 10-K 31 Mar 2025 2024 FY
2023 $801,000 -$54,000 -6.3% 01 Jan 2023 31 Dec 2023 10-K 31 Mar 2025 2024 FY
2022 $855,000 +$131,000 +18% 01 Jan 2022 31 Dec 2022 10-K 28 Mar 2024 2023 FY
2021 $724,000 +$62,000 +9.4% 01 Jan 2021 31 Dec 2021 10-K 29 Mar 2023 2022 FY
2020 $662,000 +$311,000 +89% 01 Jan 2020 31 Dec 2020 10-K 23 Mar 2022 2021 FY
2019 $351,000 01 Jan 2019 31 Dec 2019 10-K 17 Mar 2021 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.